USA flag logo/image

An Official Website of the United States Government

iGenomeTM Software Platform Prototype for Individual Genetic Health Assessment

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
89272
Program Year/Program:
2008 / SBIR
Agency Tracking Number:
HG004678
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
3RD MILLENNIUM, INC
3RD MILLENNIUM, INC 391 TOTTEN POND RD, STE 104 WALTHAM, MA 02451
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2008
Title: iGenomeTM Software Platform Prototype for Individual Genetic Health Assessment
Agency: HHS
Contract: 1R43HG004678-01
Award Amount: $353,638.00
 

Abstract:

DESCRIPTION (provided by applicant): Sufficient general clinical knowledge, DNA sequence technology and understanding of genetic mutations for over 2,600 human genes can support beginning the integration of individual genome sequence into clinical practic e for a number of medical specialties. With the 2007 deployment of novel DNA sequence technologies that permit cost-effective interrogation of individual genome sequence for the subset of the genome of clinical interest, the potential for rapid impact on p atient care is palpable. However, the lack of a suitable human genome analysis and interpretation platform is a substantial barrier that will slow implementation as these new sequence technologies are adopted. To address this gap, we plan to create a comme rcial software platform supporting the input, analysis, storage and reporting of individual human genome sequence providing a genetic health assessment for nucleotide sequence attributes that may be either assets or liabilities depending on clinical contex t. This sixteen- month SBIR Phase I proposal will support the development of a software prototype capable of supporting collaboration studies and will compile the information necessary for our first pilot study, individual genome analysis for the Hemostasi s and Thrombosis clinical area selected based on its suitability for early studies in human systems biology that would potentially have rapid clinical utility. The challenges to be addressed in the phase I effort are first to develop applications capable o f highly accurate, automated identification, extraction and ordered storage of individual human variation data followed by the testing of these variations against a knowledgebase of previously characterized human mutations and variations associated with he ritable diseases. Additional challenges will be to structure phenotypic and mutation information into formats useful to researchers and clinicians. Successful completion of the phase I effort will result in comprehensive identification of DNA sequence vari ation from individual genome sequence data and the determination of performance metrics that will be feasible to scale in phase II for the commercial software platform development capable of processing a target minimum of 100 individual genomes per day. Th e impact of this work will be to initially facilitate human systems biology studies that will demonstrate how such results can be utilized for diagnosis, prognosis and development of personalized therapeutic plans and ultimately, support diagnostic procedu res. The software prototype and the first release of the commercial grade software will make key contributions to bringing personalized medicine to the bedside in the next five years. PUBLIC HEALTH RELEVANCE: Our knowledge of genetic contributions to disea se and health is multifaceted and forms a broad spectrum; however, to apply this knowledge directly to improve health and impact patient care, the means to produce individual human genome sequence data, analyze the data and formulate the results into meani ngful reports requires complex software and information systems which do not yet exist. The software and information technologies we propose to develop will contribute to the understanding of individual genetic variation and it application for diagnostics, determining disease prognosis and for selecting individualized treatment programs. Potential application of computationally structured knowledge and individual genome data can be applied across every therapeutic area and branch of medicine; this work comp lements the Biomedical Information Science and Technology Initiative (BISTI) and strongly supports the National Institutes of Health RoadMap objectives.

Principal Investigator:

Business Contact:


rcarel@3rdmill.com
Small Business Information at Submission:

3RD MILLENNIUM, INC
3RD MILLENNIUM, INC 391 TOTTEN POND RD, STE 104 WALTHAM, MA 02451

EIN/Tax ID: 043217231
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No